^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    reozalimab (IBI318)

    i
    Other names: IBI318, IBI 318, LY3434172
    Associations

    News

    Trials
    Company:
    Eli Lilly, Innovent Biologics
    Drug class:
    PD1 inhibitor, PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; Trial completion date: Nov 2023 --> Dec 2025 | Trial primary completion date: Aug 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    10ms
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    2years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; Trial primary completion date: Apr 2022 --> Mar 2023
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    2years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1; N=30 --> 100
    Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR T790M • PD-L1 negative • ALK fusion • ROS1 fusion • ALK-ROS1 fusion
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    over2years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P1, N=30, Recruiting, Hunan Province Tumor Hospital | Phase classification: P2 --> P1 | Initiation date: Mar 2021 --> Aug 2021
    Clinical • Phase classification • Trial initiation date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)
    3years
    The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC. (clinicaltrials.gov)
    P2, N=30, Recruiting, Hunan Province Tumor Hospital
    Clinical • New P2 trial
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    Lenvima (lenvatinib) • reozalimab (IBI318)